RET and non-small cell lung carcinoma: 6.1.Selpercatinib indications funded by SNS in Spain, according to EMA Data Sheet:SNS indication #1: Selpercatinib monotherapy is indicated for treatment of patients with RET fusion-positive advanced NSCLC not previously treated with a RET inhibitor.